CTI Biopharma reported $17.09M in Gross Profit on Sales for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
Baxter International BAX:US USD 1.15B 310M
Bristol Myers Squibb BMY:US USD 8.86B 345M
CTI Biopharma CTIC:US USD 17.09M 5.68M
Eli Lilly And LLY:US USD 5.36B 305M
Novartis NOVN:VX USD 9.18B 151M
Novartis NVS:US USD 9.18B 151M
Seattle Genetics SGEN:US USD 402.18M 10.78M
Teva Pharmaceutical Industries TEVA:US USD 1.71B 118M
YTE INCY:US USD 774.02M 92.14M